Singapore markets closed

LLY Jan 2026 660.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
309.340.00 (0.00%)
As of 02:04PM EDT. Market open.
Full screen
Previous close309.34
Open309.34
Bid273.00
Ask281.00
Strike660.00
Expiry date2026-01-16
Day's range309.34 - 309.34
Contract rangeN/A
Volume1
Open interest19
  • Barrons.com

    Don’t Fret About Eli Lilly and Novo’s Weight-Loss Drug Rivals, Analyst Says

    UBS expects the two to form a duopoly for years to come, predicting ‘limited penetration’ from new entrants until 2029..

  • The Telegraph

    How a single daily pill could soon be the future of losing weight

    When Ian Strachan first started informing patients of how to secure weight-loss drugs at his pharmacies, he quickly realised that demand was strongest among one particular group.

  • Yahoo Finance Video

    CrowdStrike outage, Biden, Fifth Third Bank CEO: Catalysts

    Global IT outages caused by a CrowdStrike (CRWD) update to Microsoft Windows systems (MSFT) are rippling through major industries, causing massive issues from grounded planes to down 9-1-1 call centers. CrowdStrike management has addressed the outage as an incident related to an update, not a cyberattack. Although the CME FedWatch tool puts the probability of an interest rate cut at nearly 100% in September, there is still much uncertainty around ongoing geopolitical conflicts and the upcoming election in November. With so much that could happen in the second half of the year, investors are looking for strategies to solidify their positions. ProShares global investment strategist Simeon Hyman joined the show to break down some of the best strategies investors should consider heading into the second half of 2024. Shares of oil field services company Halliburton (HAL) fell after its second quarter revenue fell short of Street estimates. Its North America revenue declined 3% to $2.5 billion sequentially while international revenue rose 3% to $3.4 billion. Shares of Eli Lilly (LLY) are soaring after the pharmaceutical giant received regulatory approval in China for its GLP-1 weight-loss drug, Zepbound. Fifth Third Bancorp (FITB) recently posted its second quarter earnings, revealing total revenue of $2.08 billion, just below estimates of $2.12 billion. Net income available to common shareholders was $561 million, a 17% increase compared to the previous quarter. Fifth Third Bancorp CEO Tim Spence sits down with Yahoo Finance executive editor Brian Sozzi to discuss the regional bank's performance as well as how it is preparing for uncertainty related to the Federal Reserve's interest rate environment and the 2024 election. For more expert insight and the latest market action, click here. This post was written by Nicholas Jacobino